MVA-BN vaccine:
The World Health Organization (WHO) has prequalified the Danish MVA-BN vaccine, making it the first approved vaccine to combat mpox.
- This prequalification facilitates broader and faster access to the vaccine, particularly for high-risk populations, aiming to reduce transmission and contain outbreaks.
- The MVA-BN vaccine, developed by Bavarian Nordic A/S, shows 76% effectiveness with a single dose and 82% with two doses.
- The vaccine can be stored at 2-8°C for up to eight weeks and is recommended for adults over 18.
